Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA Meeting Abstract
| Authors: | Dickler, M. N.; Saura, C.; Oliveira, M.; Richards, D. A.; Krop, I. E.; Cervantes, A.; Stout, T. J.; Jin, H.; Savage, H. M.; Wilson, T. R.; Baselga, J. |
| Abstract Title: | Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA |
| Meeting Title: | 2016 San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 77 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2016 Dec 6-10 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2017-02-01 |
| Language: | English |
| ACCESSION: | WOS:000397999002314 |
| DOI: | 10.1158/1538-7445.sabcs16-p6-12-01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P6-12-01 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
